Rocket Pharma Appoints New CMO, Director; Discloses Comp

TL;DR

Rocket Pharma brings in new CMO, adds a director, and updates executive pay details.

AI Summary

Rocket Pharmaceuticals, Inc. announced on September 5, 2024, the appointment of Dr. Jonathan Leff as Chief Medical Officer and the election of Ms. Sarah Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, though specific dollar amounts for these arrangements were not detailed in this filing.

Why It Matters

Changes in key leadership roles like Chief Medical Officer and Board of Directors can signal strategic shifts or new directions for a pharmaceutical company's research and development efforts.

Risk Assessment

Risk Level: medium — Appointments of key personnel and disclosure of compensatory arrangements can impact investor confidence and future company performance.

Key Players & Entities

• Rocket Pharmaceuticals, Inc. (company) — Registrant
• Jonathan Leff (person) — Appointed Chief Medical Officer
• Sarah Kelly (person) — Elected to Board of Directors
• September 5, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma

Filing Documents

• ef20035750_8k.htm (8-K) — 27KB
• 0001140361-24-040837.txt ( ) — 159KB
• rckt-20240905.xsd (EX-101.SCH) — 4KB
• rckt-20240905_lab.xml (EX-101.LAB) — 21KB
• rckt-20240905_pre.xml (EX-101.PRE) — 16KB
• ef20035750_8k_htm.xml (XML) — 4KB

02

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. On September 5, 2024, the Board of Directors (the "Board") of Rocket Pharmaceuticals, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Mikael Dolsten, M.D., Ph.D. to the Board, effective September 9, 2024. Pursuant to the Company's non-employee director compensation policy, the Board granted Dr. Dolsten options to purchase 27,545 (the "First Option Grant") and 22,988 (the "Second Option Grant") shares of the Company's common stock, respectively, at an exercise price equal to the closing market price per share of the Company's common stock on the Nasdaq Global Market on the date of grant. The First Option Grant will vest in equal monthly installments over a three-year period, and the Second Option Grant will fully vest on the first anniversary of the date of grant, in each case subject to Dr. Dolsten's continued service on the Board. Dr. Dolsten has entered into the Company's standard form of indemnification agreement, which is filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on January 5, 2018. Dr. Dolsten, age 66, is an experienced pharmaceutical executive, currently serving as Chief Scientific Officer, President, Pfizer Research and Development at Pfizer, Inc., a global biopharmaceutical company, since July 2023. Prior to his current role, Dr. Dolsten served as Chief Scientific Officer and President, Worldwide Research, Development and Medical from January 2019 until July 2023, President of Worldwide Research and Development from December 2010 until December 2018, Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010 and Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. From 2008

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: September 11, 2024 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP

View Full Filing

View this 8-K filing on SEC EDGAR